Literature DB >> 13915098

Bretylium tosylate in treatment of severe hypertension.

K SOMERS.   

Abstract

Entities:  

Keywords:  HYPERTENSION/therapy; SYMPATHOLYTICS/therapy

Mesh:

Substances:

Year:  1962        PMID: 13915098      PMCID: PMC1957504          DOI: 10.1136/bmj.1.5282.911

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


× No keyword cloud information.
  8 in total

1.  Darenthin: hypotensive agent of new type.

Authors:  A L BOURA; A F GREEN; A McCOUBREY; D R LAURENCE; R MOULTON; M L ROSENHEIM
Journal:  Lancet       Date:  1959-07-11       Impact factor: 79.321

2.  Some pharmacological actions of bretylium and guanethidine.

Authors:  J VERNIKOS-DANELLIS; E ZAIMIS
Journal:  Lancet       Date:  1960-10-08       Impact factor: 79.321

3.  Muscle weakness caused by bretylium tosylate.

Authors:  E D CAMPBELL; E MONTUSCHI
Journal:  Lancet       Date:  1960-10-08       Impact factor: 79.321

4.  Mecamylamine and reserpine in the management of severe and malignant hypertension in Uganda.

Authors:  K SOMERS
Journal:  S Afr Med J       Date:  1959-06-20

5.  Sympathetic blockade in treatment of hypertension. Clinical trial of bretylium tosylate.

Authors:  C P LOWTHER; R W TURNER
Journal:  Br Med J       Date:  1960-10-08

6.  The interaction of bretylium with pressor agents.

Authors:  D R LAURENCE; R E NAGLE
Journal:  Lancet       Date:  1961-03-18       Impact factor: 79.321

7.  Bretylium tosylate in the treatment of hypertension.

Authors:  C T DOLLERY; D EMSLIE-SMITH; J McMICHAEL
Journal:  Lancet       Date:  1960-02-06       Impact factor: 79.321

8.  Bretylium tosylate as an antihypertensive drug.

Authors:  R E HURLEY; I H PAGE; H P DUSTAN
Journal:  J Am Med Assoc       Date:  1960-04-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.